Active Ulcerative Colitis Uc clinical trials

Explore recruiting active ulcerative colitis uc clinical trials.

Recruiting active ulcerative colitis uc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Active Ulcerative Colitis Uc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

Austria, Poland, Croatia, Netherlands, Germany, Greece +12 more

Therapeutic exploratory (Phase II) EU CTIS Study details

VERDICT: In actiVE ulcerative colitis, a RanDomIzed Controlled Trial for determination of the optimal treatment target

Italy, Belgium, France, Netherlands, Poland

Therapeutic use (Phase IV) EU CTIS Study details

An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis

Germany, Poland, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

C5041012 (APD334-303) - An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis

Poland, Portugal, Hungary, Czechia, Romania, Slovakia +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric Participants with Crohn’s Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

Spain, Germany, Poland, Italy, Norway, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Ulcerative Colitis

Sweden, Greece, Germany, Italy, Belgium, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Active Ulcerative Colitis Uc trials by city

Active Ulcerative Colitis Uc in Toronto Active Ulcerative Colitis Uc in Vancouver Active Ulcerative Colitis Uc in Montreal Active Ulcerative Colitis Uc in Calgary Active Ulcerative Colitis Uc in Edmonton Active Ulcerative Colitis Uc in Ottawa Active Ulcerative Colitis Uc in Winnipeg Active Ulcerative Colitis Uc in Quebec City Active Ulcerative Colitis Uc in Hamilton Active Ulcerative Colitis Uc in Kitchener Active Ulcerative Colitis Uc in London Active Ulcerative Colitis Uc in Halifax Active Ulcerative Colitis Uc in New York Active Ulcerative Colitis Uc in Los Angeles Active Ulcerative Colitis Uc in Chicago Active Ulcerative Colitis Uc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease